Evidence map›Paper›PMID 37432545›Full record

ArticleBreast cancer research and treatment2023

Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation.

Joanne Kotsopoulos, Jacek Gronwald, Tomasz Huzarski, Amber Aeilts, Susan Randall Armel, Beth Karlan, Christian F Singer, Andrea Eisen, Nadine Tung, Olufunmilayo Olopade and 12 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Cost-effectiveness analysis of population-basedFrontiers in public health · 2025
    Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 16 institutions in 5 countries.

Joanne KotsopoulosWomen's College Research Institute, Women's College Hospital, Toronto, ON, Canada.
Jacek GronwaldInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Tomasz HuzarskiInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Amber AeiltsDivision of Human Genetics, The Ohio State University Medical Center, Comprehensive Cancer Center, Columbus, OH, USA.
Susan Randall ArmelBhalwani Familial Cancer Clinic, Princess Margaret Cancer Centre, Toronto, Canada.
Beth KarlanDavid Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
Christian F SingerDepartment of Obstetrics and Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Andrea EisenToronto-Sunnybrook Regional Cancer Center, Toronto, ON, Canada.
Nadine TungBeth Israel Deaconess Medical Center, Boston, MA, USA.
Olufunmilayo OlopadeDepartment of Medicine and Human Genetics, University of Chicago, Chicago, IL, USA.
Louise BordeleauDepartment of Oncology, Juravinski Cancer Centre and McMaster University, Hamilton, ON, Canada.
Charis EngGenomic Medicine Institute and Center for Personalized Genetic Healthcare, Cleveland Clinic, Cleveland, USA.
William D FoulkesDepartment of Oncology, McGill Program in Cancer Genetics, McGill University, Montreal, QC, Canada.
Susan L NeuhausenDivision of Biomarkers of Early Detection and Prevention, City of Hope, Duarte, USA.
Carey A CullinaneTodd Cancer Institute, Long Beach Memorial Hospital, Long Beach, CA, USA.
Tuya PalDepartment of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Robert FruscioClinic of Obstetrics and Gynecology, Department of Medicine and Surgery, University of Milan Bicocca, Monza, Italy.
Jan LubinskiInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Kelly MetcalfeWomen's College Research Institute, Women's College Hospital, Toronto, ON, Canada.
Ping SunWomen's College Research Institute, Women's College Hospital, Toronto, ON, Canada.
Steven A NarodWomen's College Research Institute, Women's College Hospital, Toronto, ON, Canada. steven.narod@wchospital.ca.ORCID http://orcid.org/0000-0001-5798-0626
and the Hereditary Breast Cancer Clinical Study Group
International Hereditary Cancer Center · PLUniversity of Toronto · CAVanderbilt University Medical Center · USWomen's College Hospital · CABeth Israel Deaconess Medical Center · USCity of Hope · USCleveland Clinic · USComprehensive Cancer Center Vienna · ATJuravinski Cancer Centre · CAMcGill University · CAMemorialCare Long Beach Medical Center · USSunnybrook Health Science Centre · CAThe Ohio State University Wexner Medical Center · USUniversity of California, Los Angeles · USUniversity of Chicago · USUniversity of Milano-Bicocca · IT

Funding

CIHR FDN 154275
6 · The paper itself

Abstract

purposeChemoprevention with a selective estrogen receptor modulator (tamoxifen or raloxifene) is a non-surgical option offered to high-risk women to reduce the risk of breast cancer. The evidence for tamoxifen benefit is based on trials conducted among predominantly postmenopausal women from the general population and on studies of contralateral breast cancer in women with a pathogenic variant (mutation hereafter) in BRCA1 or BRCA2. Tamoxifen has not been assessed as a primary prevention agent in women with an inherited BRCA mutation.

methodsWe conducted a prospective analysis of tamoxifen chemoprevention and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation. Data on tamoxifen (and raloxifene) use was collected by questionnaire and updated biennially. Information on incident cancers was collected by self-report and was confirmed by medical record review. In a matched analysis, we estimated the hazard ratio (HR) and 95% confidence intervals (CI) for developing a first primary breast cancer associated with tamoxifen or raloxifene use, using Cox proportional hazards analysis.

resultsThere were 4578 unaffected women in the cohort, of whom 137 reported tamoxifen use (3%), 83 reported raloxifene use (2%) and 12 used both drugs (0.3%). Women who used tamoxifen or raloxifene were matched 1:3 with women who used neither drug on year of birth, country of residence, year of study entry and gene (BRCA1 or BRCA2). We generated 202 matched pairs. After a mean follow-up of 6.8 years, there were 22 incident breast cancers diagnosed among tamoxifen/raloxifene users (10.9% of users) and 71 cases diagnosed among non-users (14.3% of non-users; HR = 0.64; 95% CI 0.40-1.03; P = 0.07).

conclusionChemoprevention may be an effective risk-reduction option for BRCA mutation carriers, but further studies with longer follow-up are necessary.

Indexed as

Breast NeoplasmsTamoxifenBRCA1 ProteinBRCA2 ProteinFemaleGenes, BRCA1HumansMutationRaloxifene HydrochlorideRisk FactorsBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanRaloxifene HydrochlorideTamoxifenBRCA1BRCA2Breast cancerChemopreventionRaloxifeneTamoxifen

Identifiers

PMID37432545
OpenAlexW4383873232

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.